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Abstract: To control the Human Immunodeficiency Virus (HIV) pandemic, the World Health Organi-
zation (WHO) set the 90-90-90 target to be reached by 2020. One major threat to those goals is late
presentation, which is defined as an individual presenting a TCD4+ count lower than 350 cells/mm3
or an AIDS-defining event. The present study aims to identify determinants of late presentation in
Europe based on the EuResist database with HIV-1 infected patients followed-up between 1981 and
2019. Our study includes clinical and socio-demographic information from 89,851 HIV-1 infected
patients. Statistical analysis was performed using RStudio and SPSS and a Bayesian network was
constructed with the WEKA software to analyze the association between all variables. Among 89851
HIV-1 infected patients included in the analysis, the median age was 33 (IQR: 27.0–41.0) years and
74.4% were males. Of those, 28,889 patients (50.4%) were late presenters. Older patients (>56),
heterosexuals, patients originated from Africa and patients presenting with log VL >4.1 had a higher
probability of being late presenters (p < 0.001). Bayesian networks indicated VL, mode of transmis-
sion, age and recentness of infection as variables that were directly associated with LP. This study
highlights the major determinants associated with late presentation in Europe. This study helps to
direct prevention measures for this population.
Keywords: HIV-1 infection; late presentation; Europe
1. Introduction
At the end of 2019, there were 38.0 million people living with the Human Immunod-
eficiency Virus (HIV) and 1.7 million people were newly infected worldwide. However,
7.1 million people were still unaware of their HIV status [1].
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For the control of the HIV pandemic, the World Health Organization (WHO) had set
a 90-90-90 target until 2020. 90% of people living with HIV know their status, of those
90% are receiving antiretroviral therapy (ART) and of those 90% achieve viral suppression.
These targets had been successful in some countries. Globally, by the end of 2019, there
were 81% of people living with HIV who knew their status. Of those, 67% were receiving
antiretroviral therapy and of those 59% had reached HIV viral suppression. The success of
these goals is dependent on the region of origin, the vulnerability of populations and on the
national HIV programs that are implemented. Yet, between 2010 and 2019, the percentage
of new infections dropped by 31% [2].
New goals were set to end the pandemic by 2030, the 95-95-95 targets, based on the
same definition of the previous targets. In order to attain the WHO goals by 2030, early
diagnosis is essential [3].
One major concern threatening those goals is late presentation. Late presentation can
have consequences in the health and treatment of infected individuals, leading to poorer
outcomes and increased health care costs, since it has been shown that late presenters,
especially those aged above 50 years old, are at higher risk for developing non-infectious
co-morbidities and complex multimorbidity [4]. In addition, late presentation can have
a negative impact on the control of the pandemic, increasing the risk of onward HIV
transmission in individuals that are not aware of their HIV status. Besides, late presentation
to HIV care was shown to be the main reason for virological failure [5,6].
Late presentation is defined as an individual presenting a TCD4+ count lower than
350 cells/mm3 or an AIDS-defining event, regardless of TCD4+ cell count. This is the
definition according to the European Late Presenter Consensus working group [7]. It is
estimated that Late Presenters (LP) account for 40–60% of HIV cases in Europe, in Asia the
percentage of LP range from 72 to 83%, in Africa range from 35 to 89% and in Brazil, it
is estimated that the percentage is near 40% [8–10]. For prevention and treatment of HIV,
timely diagnosis and linkage to health care are essential tools [11].
The present study has the objective of identifying determinants of late presentation
in Europe. To achieve this goal, we analyzed a population of patients from the EuResist
database, a European database.
2. Results
2.1. Characteristics of European Population
Among 89851 HIV-1 infected patients included in the analysis, the median age was
33 (IQR: 27.0–41.0) years and 74.4% were males. From those 28889 patients (50.4%) were
LP and 28388 (49.6%) were non-late presenters (NLP). The majority of patients with in-
formation about treatment status were naïve, 11487 (58.6%). 41.9% of patients were men
who have sex with men (MSM) and 78.5% originated from Western Europe. The most
prevalent subtype in this population was subtype B (64.4%), followed by Subtype G (20.4%),
CRF 02_AG (15.9%) and Subtype A (13.5%). Most of the patients included in this study
were classified as Native (75.4%) and as having Chronic Infection (59.8%) based on the
ambiguity rate of the first genomic sequence. CD4 count at diagnosis and viral load at
diagnosis (log10) presented a median of 348 cells/mm3 (IQR 170-548) and 4.4 copies/mL
(IQR 3.4–5.1), respectively.
50.4% of patients were classified as LP (CD4 < 350 cells/mm3). Males accounted for
the higher proportion of LP (74.9%). The median age of LPs was 34 years (IQR 28.0–43.0;
p < 0.001). LPs were mainly from Western Europe and the HIV exposure category was
mainly heterosexuals (77.4 and 37.1%; p < 0.001, respectively) (Table 1).
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Table 1. Demographic and patient characteristics. Other in mode of transmission includes blood transfusions and vertical
transmission. Other in region of origin and infection includes North and Central America, Asian and Oceania continents.
p-values retrieved with chi-square test and Mann–Whitney U test.
Patient Characteristics Total Late Presenters Non-LatePresenters p-Value
Total, n (%) 89,851 (100%) 28,889 (50.4%) 28,388 (49.6%)
Sex, n (%) 81,777 (91.0%) 27,972 (50.6%) 27,315 (49.4%)
<0.001Male 60,852 (74.4%) 20,955 (74.9%) 20,969 (76.8%)
Female 20,925 (25.6%) 7017 (25.1%) 6346 (23.2%)
Treatment status, n (%) 19,605 (21.8%) 10,905 (55.6%) 8700 (44.4%)
<0.001Naïve 11,487(58.6%) 6040 (55.4%) 5447 (62.6%)
Treated 8118 (41.4%) 4865 (44.6%) 3253 (37.4%)
Median age at diagnosis in years
IQR, n (%)
25,530 (28.4%) 11,929 (52.3%) 10,897 (47.7%)
<0.00133.0 (27.0–41.0) 34.0 (28.0–43.0) 31.0 (26.0–39.0)
≤18 700 (2.7%) 241 (2.0%) 340 (3.1%)
<0.001
19–30 9767 (38.3%) 4002 (33.5%) 4823 (44.3%)
31–55 13,815 (54.1%) 6920 (58.0%) 5384 (49.4%)
≥56 1248 (4.9%) 766 (6.4%) 350 (3.2%)
Mode of transmission, n (%) 47,007 (52.3%) 21,283 (49.5%) 21,677 (50.5%)
<0.001
Heterosexual 15,165 (32.3%) 7894 (37.1%) 6071 (28.0%)
MSM 19,696 (41.9%) 7657 (36.0%) 10,693 (49.3%)
IDU 9532 (20.3%) 4453 (20.9%) 3896 (18.0%)
Other 2614 (5.6%) 1279 (6.0%) 1017 (4.7%)
Region of origin, n (%) 54,529 (60.7%) 21,584 (50.1%) 21,495 (49.9%)
<0.001
Western Europe 42,790 (78.5%) 16,693 (77.4%) 17,398 (81.0%)
Eastern Europe 1862 (3.4%) 693 (3.2%) 672 (3.1%)
Africa 5349 (9.8%) 2250 (10.4%) 1422 (6.6%)
South America 3233 (5.9%) 1341 (6.2%) 1460 (6.8%)
Other 1286 (2.4%) 607 (2.8%) 543 (2.5%)
Subtype, n (%) 54,176 (60.3%) 17,449 (52.7%) 15,638 (47.3%)
<0.001HIV-1 Subtype B 35,454 (64.4%) 11,966 (68.6%) 11,745 (75.1%)
HIV-1 Subtype non-B 18,722 (34.6%) 5483 (31.4%) 3893 (24.9%)
Distribution of non-B Subtypes
HIV-1 CRF 01_AE 447 (2.4%) 183 (3.3%) 108 (2.8%)
HIV-1 CRF 02_AG 2973 (15.9%) 871 (15.9%) 556 (14.3%)
HIV-1 CRF 06_cpx 248 (1.3%) 81 (1.5%) 58 (1.5%)
HIV-1 CRF 14_BG 1106 (5.9%) 337 (6.1%) 203 (5.2%)
HIV-1 Subtype A 2521 (13.5%) 626 (11.4%) 527 (13.5%)
HIV-1 Subtype C 1943 (10.4%) 550 (10.0%) 400 (10.3%)
HIV-1 Subtype D 307 (1.6%) 102 (1.9%) 74 (1.9%)
HIV-1 Subtype F 1619 (8.6%) 444 (8.1%) 362 (9.3%)
HIV-1 Subtype G 3815 (20.4%) 1156 (21.1%) 701 (28.0%)
Others 3743 (20.0%) 1133 (20.7%) 3893 (23.2%)
Migrant status, n (%) 54,520 (60.7%) 21,584 (50.1%) 21,495 (49.9%)
<0.001Migrant 13,408 (24.6%) 5588 (25.9%) 4895 (22.8%)
Native 41,112 (75.4%) 15,996 (74.1%) 16,600 (77.2%)
Recentness of infection, n (%) 50,132 (55.8%) 15,897 (52.6%) 14,304 (47.4%)
<0.001Chronic 29,972 (59.8%) 11,069 (69.6%) 7803 (54.6%)
Recent 20,160 (40.2%) 4828 (30.4%) 6501 (45.4%)
Median CD4 count at diagnosis
(cells/mL) IQR, n (%)
57,277 (63.7%) 28,889 (50.4%) 28,388 (49.6%)
<0.001348.0 (170.0–548.0) 172.0 (69.0–264.0) 550.0 (442.0–720.0)
Viral Load at diagnosis (log10
copies/mL) IQR, n (%)
34,046 (37.9%) 15,106 (50.8%) 14,605 (49.2%)
<0.0014.4 (3.4–5.1) 4.7 (3.8–5.3) 4.1 (3.1–4.8)
≤4.0 12,994 (38.2%) 4485 (29.7%) 6819 (46.7%)
<0.0014.1–5.0 11,715 (34.4%) 5034 (33.3%) 5295 (36.3%)
≥5.1 9337 (27.4%) 5587 (37.0%) 2491 (17.1%)
Pathogens 2021, 10, 835 4 of 13
2.2. Determinants Associated with Late Presentation
In the unadjusted model (Table 2), sex was associated with LP. In the HIV exposure
category, significant differences were found for MSM and Intravenous Drug Users (IDU)
compared with heterosexuals. Significantly more LP were from Africa and other regions
compared to Western Europe. In addition, the variables age at diagnosis, viral load, subtype,
recentness of infection and migrant status were significantly associated with LP.
Table 2. Logistic Regression for determinants associated with late presentation. Ref—Reference category; aOR-adjusted
Odds Ratio; Other in mode of transmission include transfusions; Other in region of origin include Latin and North American
Countries; MSM- Men have sex with men; IDU- Injection drug users.
Late Presenters/
Non-Late Presenters Unadjusted Final Model
Variable OR (95%CI) p-Value aOR (95%CI) p-Value
Sex
Female Ref Ref Ref Ref
Male 0.90 (0.87–0.94) <0.001 1.05 (0.91–1.21) 0.522
Age at diagnosis 1.03 (1.02–1.03) <0.001
Age groups
<18 0.55 (0.47–0.65) <0.001 0.48 (0.33–0.69) <0.001
19–30 0.65 (0.61–0.68) <0.001 0.70 (0.63–0.79) <0.001
31–55 Ref Ref Ref Ref
>56 1.70 (1.49–1.94) <0.001 1.54 (1.15–2.06) 0.004
Mode of transmission
Heterosexual Ref Ref Ref Ref
MSM 0.55 (0.53–0.58) <0.001 0.74 (0.64–0.86) <0.001
IDU 0.88 (0.83–0.93) <0.001 1.12 (0.96–1.31) 0.137
Other 0.97 (0.88–1.06) 0.462 1.29 (0.99–1.70) 0.062
Region of Origin
Western Europe Ref Ref Ref Ref
Eastern Europe 1.08 (0.97–1.20) 0.191 1.07 (0.78–1.48) 0.683
Africa 1.65 (1.54–1.77) <0.001 1.76 (1.37–2.26) <0.001
South America 0.96 (0.89–1.03) 0.267 1.41 (1.07–1.87) 0.015
Other 1.17 (1.04–1.31) 0.011 1.39 (0.92–2.09) 0.118
Subtype
HIV-1 Subtype B Ref Ref
HIV-1 Subtype non-B 1.38 (1.32–1.45) <0.001
Migrant Status
Migrant Ref Ref
Native 0.84 (0.81–0.88) <0.001
Recentness of infection
Chronic Ref Ref Ref Ref
Recent 0.52 (0.50–0.55) <0.001 0.61 (0.55–0.68) <0.001
Log Viral load at diagnosis 1.45 (1.42–1.48) <0.001
Log Viral load groups
<4.0 Ref Ref Ref Ref
4.1–5.0 1.45 (1.37–1.53) <0.001 1.37 (1.22–1.55) <0.001
>5.1 3.41 (3.21–3.62) <0.001 3.41 (2.96–3.91) <0.001
Determinants associated with late presentation were age at diagnosis (Table 2): pa-
tients with less than 30yo had lower probability of being late presenters and patients aged
above 56yo had higher probability of being late presenters when compared with patients
aged between 31 and 55yo (>18yo: aOR 0.31 (0.20–0.49), p < 0.001; 19–30yo: aOR 0.46
(0.34–0.62), p < 0.001; >56: aOR 1.70 (1.49–1.94), p = 0.004), transmission via MSM had lower
probability when compared with heterosexuals (aOR 0.74 (0.64–0.86); p < 0.001). Patients
originating from Africa and South America had 1.76 and 1.41 more probability, respectively,
of presenting late than those from Western Europe (aOR 1.76 (1.37–2.26), p < 0.001; aOR
1.41 (1.07–1.87), p = 0.015, respectively) and patients presenting with a viral load between
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4.1 and 5.0 and higher than 5.1 had a higher probability of being LP than those with a viral
load lower than 4.0 (aOR 1.45 (1.37–1.53) and aOR 3.41 (3.21–3.62); p < 0.001 and p < 0.001,
respectively). As expected, but confirming the reliability of our classification of recentness
of infection based on the ambiguity rate, patients with a recent infection—as classified
based on the ambiguity rate of the genomic sequence from the first drug resistance test—
had a lower probability of being LP than those classified as being chronically infected (aOR
0.61 (0.55–0.68); p < 0.001).
2.3. Bayesian Network
For the bayesian network, we used the HillClimber algorithm with nine as the maxi-
mum number of parents a node in BN can have. This algorithm is based on a “hill climbing
adding and deleting arcs with no fixed ordering of variables” [12]. The BN had a LogScore
Bayes of −35615.94 and an accuracy of 61%. In the BN (Figure 1), LPs are directly associated
with the viral load, recentness of infection, mode of transmission and age, as we can see in
the figure below, those were direct links between the nodes. The indirectly associated links
were between LP and region of origin. As we can also see in the figure, there was no direct
link between those two nodes. We can see that the mode of transmission is the variable
with more direct associations and the variable sex is the only one that is not associated with
LP. This BN is in accordance with our logistic regression model.
Figure 1. Bayesian Network analysis of association between variables investigated in the study. The BayesNet classifier
and the HillClimber algorithm were used as implemented in the WEKA software. LP—Late Presenters; VL—Viral Load;
MT—Mode of Transmission; RI—Recentness of infection; RO—Region of Origin; MS—Migrant Status.
The variables Subtype and Migrant status had been removed from the logistic regres-
sion model due to the conflict with the variable region of origin. As we can see in Figure 1,
the region of origin is directly associated with those two variables and that the migrant
status is only associated with region of origin.
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2.4. Ambiguity Rate and CD4 Analysis
We performed an analysis to understand the association between CD4 count and the
ambiguity rate overall and on subtype B, non-B and G. This association was inversely pro-
portional in all correlations, this means that for higher values of CD4 count the ambiguity
rate is lower. In this study, the LP population had higher ambiguity rates in their sequences,
since their CD4 count is lower. We also performed a linear regression in order to explain
how much of the CD4 count could the ambiguity rate explain. We divided that analysis in
the same categories as mentioned above and the higher result was from only individuals
with non-B subtype, in which the ambiguity rate explained 5% of the variation from CD4
count (Tables A1–A4).
2.5. Analysis of Late Presenters Rate over Time
We also constructed a graph to evaluate the evolution in time of the rate of LP
(Figure 2). The confidence intervals were also calculated for each point. We did not
include in the analysis the first three years (1981–1983) since the total number of patients in
those years was low and the confidence intervals had high values. In 2019 the sample size
was also small, but we included this year in the analysis to see the trend that LPs in Europe
will have. As we can see in the graph, LPs have had constant values through the years. In
1984 we had 57.5% LPs, in 1991 we had the lowest value of LPs (45.1%). The evolution
through the years maintained between 45 and 60% the rate of LP. Since 2017 the rate of LPs
was growing until 2019 that peaked, beyond 60%.
Figure 2. Evolution of Late Presenters rate per Year. Vertical black lines represent confidence intervals.
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3. Discussion
This study had the goal of explaining the determinants of late presentation for HIV-1
infection in Europe.
In our population, late presenters represented 50.4% of the patients. A study in
Georgia, using the same definition of late presentation as we used, reported 63.4% of late
presenters. Another study analyzing late presentation in different settings indicated a rate
of late presentation ranging between 40 and 67%, depending on the region of study. This
study corresponded to the Swiss data incorporated in the COHERE study, a Collaboration
of Observational HIV Epidemiological Research Europe Study. Our results are concordant
with the results reported in these studies [13–15].
In our study, late presenters were more frequently males, with heterosexual transmis-
sion, from Western Europe and aged between 31 and 55 years old. In a study in East of
England, the percentage of late presenters was higher in older patients and patients with
heterosexual contact, when compared with homosexual and bisexual contact. Furthermore,
according to other studies in Poland and the Netherlands, males were also more prevalent
in the late presenters’ population. These results are consistent with our study [16–18].
Patients originated from Africa had a higher probability of being LPs when compared
to patients originated from Western Europe. This percentage of African migrants in the
LP population can be explained by the lower access to health care. Furthermore, African
migrants have a higher probability of being in conditions of unemployment, poverty
and poorer household, which further increase their barriers to access to health care. A
positive status for HIV also stigmatizes individuals, and they fear the reactions of their
communities, since HIV is mostly associated among these communities with inappropriate
and promiscuous sexual behavior [19]. The migrants of our study from South America
were mainly from Brazil and the LP rate was lower than the NLPs. This can be explained
in two ways: Brazil has a concentrated HIV epidemic among MSM population and that
population is frequently tested [20]. These results are in accordance with HIV studies about
the migrant population [21–23].
The results from a previous study showed a statistically significant correlation between
late presentation and IDUs [24]. In our study, we found this significant association between
LP and IDU in our univariate analysis, but in the logistic regression analysis, we only
found significant the association between MSM when compared to heterosexuals. The
prevalence of HIV-positive IDU population is mainly from Eastern Europe. In our study,
the IDU group maybe underrepresented since the larger proportion of cases are from
Western Europe, in which the major mode of transmission is through heterosexual and
MSM contacts [25,26].
We also studied the association between CD4 count and the ambiguity rate of the
sequences included in this study. Our results show a negative correlation between CD4
count and the ambiguity rate, for lower values of CD4 we had higher values of the
ambiguity rate. There is still little information regarding this topic, but our results were
in accordance with a study about sequence ambiguity and HIV incidence trends [27]. In
fact, the ambiguity rate could be an alternative variable to be used for the definition of Late
Presentation. As we know, the initial drop of CD4 count in the acute phase of HIV infection
can be a cause of bias when we define Late Presentation based on a CD4 count lower than
350 cells/mm3.
The results from the graph showed stable and high values for LPs rate. This indicates
that LPs were and remain a big part of the HIV epidemic and represent a major threat to
treatment and prevention strategies.
The main goal of this study was to identify determinants associated with late presen-
tation. Those determinants included age at diagnosis, mode of transmission, region of
origin, recentness of infection and viral load at diagnosis (Figure 3). Our results were in
concordance with other previously published studies [13,28,29].
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Figure 3. Schematic representation of determinants of late presentation based on logistic regression and Bayesian networks
analysis. The light grey box indicates the direct determinants, and the dark grey box indicates the indirect determinants of
late presentation. Individuals older than 56yo and originated from Africa had higher probability of being late presenters,
Men who have sex with men were less likely to be late presenters. In the clinical determinants there were only direct
associated determinants. Individuals with a viral load higher than 4.1 copies/mL had higher probability of being late
presenters and individuals with a lower rate of sequence ambiguity had lower probability of being late presenters. MSM-Men
who have sex with Men.
The last study about late presentation in Europe was published in 2015 and the
timeline of the study was between 2010 and 2013. This was an update from the first study
published in 2013, with a timeline of analysis between 2000 and 2011 [29,30]. Our study
analyzes a European database with a timeline between 1981 and 2019. The main strength
of our study was the database used, which is one of the largest datasets and integrates
clinical, socio-demographic and viral genotypic information from HIV-1 patients from all
over Europe. This large dataset allows for a robust analysis of the data, and up to date
information regarding late presentation. In addition, we can analyze trends in the evolution
of late presentation in Europe.
The major limitation of our study was the lack of information about the stage of HIV
infection and AIDS-defining events. While we used the ambiguity rate to minimize this
problem, we only used the definition of a CD4 count below 350 cells/mm3 to define an
individual as LP or NLP.
Yet, this study is the most recent update on the HIV epidemic of late presentation in
Europe, since the last one was published in 2015.
Since late presentation is a major obstacle to the 95-95-95 targets, it is necessary to
reinforce the follow-up of this population. Increased HIV testing is key to reduce late
presentation since it results in earlier HIV diagnosis. Prevention measures like targeting
the vulnerable populations and increasing screening programs for those populations are
the most urgent strategies to halt and decrease the percentage of late presenters. In low-
and middle-income countries, point-of-care testing would be a major advance to stop
the spread of the virus by those who do not know their serological status and therefore
decreasing late presentation at diagnosis.
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4. Materials and Methods
4.1. Study Group
Our study includes clinical and socio-demographic information from 89851 HIV-1
infected patients from the EuResist Integrated Database (EIDB) between 1981 and 2019.
The EuResist integrated database (EIDB) is one of the largest existing datasets which
integrate clinical, socio-demographic and viral genotypic information from HIV-1 patients.
It integrates longitudinal, periodically updated data mainly from Italy (ARCA database),
Germany (AREVIR database) Spain (CoRIS and IRISCAIXA), Sweden, Belgium, Portugal
and Luxembourg [31–33].
In this study, information from the ARCA, AREVIR, Luxembourg, IRISCAIXA, Portu-
gal, Russia, United Kingdom and CoRIS databases were used.
4.2. Subtyping
The genomic data included HIV-1 protease and reverse transcriptase sequences, gen-
erated through routine drug resistance testing and as stored in the EuResist database. Only
the first HIV genomic sequence per patient was considered.
HIV-1 subtyping was performed using the consensus of the result obtained through
three different tools: Rega HIV Subtyping Tool (https://www.genomedetective.com/app/
typingtool/hiv, accessed on 1 July 2021) [34], COMET: adaptive context-based modeling
for HIV-1 (https://comet.lih.lu, accessed on 1 July 2021) [35] and SCUEAL (http://classic.
datamonkey.org/dataupload_scueal.php, accessed on 1 July 2021).
4.3. Study Variables
We used the information from the EuResist database regarding the following variables:
Country of follow-up, Year of Birth, Gender, Country of Origin, Mode of transmission,
Date of the first HIV Positive test, Date and value of the first CD4 count, Date and value
of the first Viral Load count, first genomic sequence and sample collection date, Date of
therapy initiation.
With this information we created new variables such as:
• Migrant/Native-Based on Country of Origin and Country of Follow-up (if country of
origin and country of follow-up is the same, then patient is native; if country of origin
and country of follow-up is not the same, then patient is migrant)
• Age at Diagnosis-Based on the difference between Year of Birth and Date of the first
HIV Positive test;
• Region of Origin- Based on Country of Origin;
• Treatment Status at date of first CD4 count-Based on the difference between sample
collection date of first CD4 count and first therapy date; for purposes of classification
of Late Presentation, only patients naïve at date of first CD4 count were considered;
• Treatment Status at date of first Drug Resistance Test-based on the difference between
sample collection date for first drug resistance test and date of start of first therapy;
After creating these two variables, for quality control purposes, we only included in
the analysis patients for which treatment status at date of first CD4 count and Treatment
Status at date of first Drug Resistance test were consistent.
• Recentness of infection-Based on ambiguity rate of genomic sequences. We defined
Chronic infection as an ambiguity value higher than 0.45% and Recent infection as
an ambiguity value equal or below 0.45% [36]. Additionally, only genomic sequences
larger than 500 nucleotides and with ambiguity rate lower than 2.5% were considered.
• LP vs. NLP- Based on CD4 count, LP were defined as patients with CD4 count lower
than 350 cells/mm3 and NLP were defined as patients with CD4 count higher than
350 cells/mm3.
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4.4. Statistical Analysis
The proportion and median (interquartile range, IQR) of LP and non- Late presenters
(NLP) were calculated for every categorical and continuous variable, respectively. Our
interest variables were compared with the categorical variables with Chi-square test, and
continuous variables with Mann–Whitney U test.
To study the relationship between our dependent variable (LP or NLP) and the in-
dependent variables, logistic regression models were calculated. We first presented the
logistic regression with the unadjusted odds ratios (uOR) and confidence intervals at 95%
(95% CI), in order to see the probability of our event, the dependent variable, (late presenta-
tion vs non-late presentation) on the occurrence of each independent variable, individually,
e.g., the probability of a woman being late presenter. Variables with a p-value < 0.05 were
considered to enter the model since it is the most used threshold. The final model for
LP vs. NLP was adjusted for sex, this variable was forced into the model regardless of
its significance and the reference class was women. The final model included only the
variables that were considered statistically significant (p < 0.05) and the variables that suited
the best regression model according to the backward stepwise regression analysis through
SPSS. The odds ratio and 95% confidence intervals were calculated for those variables as
well. Data were analyzed using RStudio (Version 1.2.5033) and SPSS (Version 26.0.0.0).
4.5. Bayesian Networks
A Bayesian network (BN) is a tool that consists of a directed acyclic graph (DAG),
made of nodes and directed links between the nodes, which allows us to understand the
representation of a probabilistic distribution. Each node is a representation of a variable,
and the links indicate that one node is directly influencing another. The lack of a direct link
does not mean that one variable is not associated with another. These networks are able
to intuitively create causal links between variables since they are built from probability
distributions and for prediction [37].
We constructed a BN to analyze the association between all variables, specifically, we
wanted to see how the variables were associated with one another. With the different levels
and connections between variables, it is possible to see if they are directly or indirectly
associated. We used the WEKA software version 3.8.5. WEKA stands for Waikato Environ-
ment for Knowledge Analysis. After the upload of the dataset, the first step is to choose
a classifier to start the analysis. We used a statistical-based learning scheme, the Bayes
classifier, specifically the BayesNet [38]. After choosing the classifier, we used different
search algorithms as a local score structure learning. Our final choice of algorithm was
based on the LogScore Bayes value and the percentage of correctly classified instances.
5. Conclusions
In summary, late presentation still accounts for 50% of the new diagnosis in Europe.
Its most important determinants are age at diagnosis, mode of transmission, region of
origin and viral load at diagnosis (Figure 3). In addition, the evolution of the rate of
late presentation through the years was stable, except for the last two years analyzed
(2018 and 2019) when that rate showed an increase. This study highlights the major
determinants associated with late presenters in Europe, and this will help to strengthen
some prevention measures.
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Appendix A
Table A1. Linear Regression for CD4 count vs. Ambiguity rate.




p-Value 95% Confidence Interval forB Spearman’s Correlation
Lower




Rate 0.023 −69.52 −0.152 <0.001 −74.61 −64.44 <0.001 −0.190
Table A2. Linear Regression for CD4 count vs. Ambiguity rate for Subtype B.




p-Value 95% Confidence Interval forB Spearman’s Correlation
Lower




Rate 0.015 −57.11 −0.123 <0.001 −63.27 −50.95 <0.001 −0.159
Table A3. Linear Regression for CD4 count vs. Ambiguity rate for Subtype non-B.




p-Value 95% Confidence Interval forB Spearman’s Correlation
Lower




Rate 0.051 −96.72 −0.226 <0.001 −105.54 −87.91 <0.001 −0.265
Table A4. Linear Regression for CD4 count vs. Ambiguity rate for Subtype G.




p-Value 95% Confidence Interval forB Spearman’s Correlation
Lower




Rate 0.014 −52.78 −0.120 <0.001 −73.38 −32.17 <0.001 −0.144
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